Rapid-sequence tandem transplant for children with high-risk neuroblastoma

Stephan A. Grupp, Julie W. Stern, Nancy Bunin, Cheryl Nancarrow, Roberta Adams, Jed B. Gorlin, Greg Griffin, Lisa Diller

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background. The majority of patients with high risk neuroblastoma (NB) still relapse. Procedure. We designed a Phase II trial for children with advanced NB utilizing a program of induction chemotherapy followed by tandem high-dose chemoradiotherapy with stem cell rescue (HDC/SCR) in rapid sequence. Fifty-five patients were evaluable, ages 1-14 years, and 97 cycles of HDC/SCR have been completed to date. Pheresis was possible for every patient, despite their young age, with an average of 7.2 x 106 CD34+ cells/kg available to support each HDC/SCR cycle. Results. Engraftment was rapid, with median time to neutrophil engraftment of 11 days. Five patients who completed the first HDC course did not complete the second and there were four toxic deaths. With a median follow-up of 24 months from diagnosis, 38 of 55 patients (3-year EFS 59%) remain event-free. A subset of the patients received stem cells purged by CD34 selection. The engraftment and EFS of these patients are similar to the overall group. Conclusion. This work demonstrates that a tandem transplant regimen for high-risk NB is a feasible treatment strategy in children and may improve disease-free survival. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)696-700
Number of pages5
JournalMedical and Pediatric Oncology
Volume35
Issue number6
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Neuroblastoma
Transplants
Chemoradiotherapy
Stem Cells
Blood Component Removal
Induction Chemotherapy
Poisons
Disease-Free Survival
Cell Cycle
Neutrophils
Recurrence

Keywords

  • CD34 selection
  • Neuroblastoma
  • Pediatric
  • Stem cell transplant
  • Tandem transplant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Grupp, S. A., Stern, J. W., Bunin, N., Nancarrow, C., Adams, R., Gorlin, J. B., ... Diller, L. (2000). Rapid-sequence tandem transplant for children with high-risk neuroblastoma. Medical and Pediatric Oncology, 35(6), 696-700. https://doi.org/10.1002/1096-911X(20001201)35:6<696::AID-MPO46>3.0.CO;2-0

Rapid-sequence tandem transplant for children with high-risk neuroblastoma. / Grupp, Stephan A.; Stern, Julie W.; Bunin, Nancy; Nancarrow, Cheryl; Adams, Roberta; Gorlin, Jed B.; Griffin, Greg; Diller, Lisa.

In: Medical and Pediatric Oncology, Vol. 35, No. 6, 2000, p. 696-700.

Research output: Contribution to journalArticle

Grupp, SA, Stern, JW, Bunin, N, Nancarrow, C, Adams, R, Gorlin, JB, Griffin, G & Diller, L 2000, 'Rapid-sequence tandem transplant for children with high-risk neuroblastoma', Medical and Pediatric Oncology, vol. 35, no. 6, pp. 696-700. https://doi.org/10.1002/1096-911X(20001201)35:6<696::AID-MPO46>3.0.CO;2-0
Grupp, Stephan A. ; Stern, Julie W. ; Bunin, Nancy ; Nancarrow, Cheryl ; Adams, Roberta ; Gorlin, Jed B. ; Griffin, Greg ; Diller, Lisa. / Rapid-sequence tandem transplant for children with high-risk neuroblastoma. In: Medical and Pediatric Oncology. 2000 ; Vol. 35, No. 6. pp. 696-700.
@article{bc5040efb40b483dbeaba8c307f3b0c2,
title = "Rapid-sequence tandem transplant for children with high-risk neuroblastoma",
abstract = "Background. The majority of patients with high risk neuroblastoma (NB) still relapse. Procedure. We designed a Phase II trial for children with advanced NB utilizing a program of induction chemotherapy followed by tandem high-dose chemoradiotherapy with stem cell rescue (HDC/SCR) in rapid sequence. Fifty-five patients were evaluable, ages 1-14 years, and 97 cycles of HDC/SCR have been completed to date. Pheresis was possible for every patient, despite their young age, with an average of 7.2 x 106 CD34+ cells/kg available to support each HDC/SCR cycle. Results. Engraftment was rapid, with median time to neutrophil engraftment of 11 days. Five patients who completed the first HDC course did not complete the second and there were four toxic deaths. With a median follow-up of 24 months from diagnosis, 38 of 55 patients (3-year EFS 59{\%}) remain event-free. A subset of the patients received stem cells purged by CD34 selection. The engraftment and EFS of these patients are similar to the overall group. Conclusion. This work demonstrates that a tandem transplant regimen for high-risk NB is a feasible treatment strategy in children and may improve disease-free survival. (C) 2000 Wiley-Liss, Inc.",
keywords = "CD34 selection, Neuroblastoma, Pediatric, Stem cell transplant, Tandem transplant",
author = "Grupp, {Stephan A.} and Stern, {Julie W.} and Nancy Bunin and Cheryl Nancarrow and Roberta Adams and Gorlin, {Jed B.} and Greg Griffin and Lisa Diller",
year = "2000",
doi = "10.1002/1096-911X(20001201)35:6<696::AID-MPO46>3.0.CO;2-0",
language = "English (US)",
volume = "35",
pages = "696--700",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Rapid-sequence tandem transplant for children with high-risk neuroblastoma

AU - Grupp, Stephan A.

AU - Stern, Julie W.

AU - Bunin, Nancy

AU - Nancarrow, Cheryl

AU - Adams, Roberta

AU - Gorlin, Jed B.

AU - Griffin, Greg

AU - Diller, Lisa

PY - 2000

Y1 - 2000

N2 - Background. The majority of patients with high risk neuroblastoma (NB) still relapse. Procedure. We designed a Phase II trial for children with advanced NB utilizing a program of induction chemotherapy followed by tandem high-dose chemoradiotherapy with stem cell rescue (HDC/SCR) in rapid sequence. Fifty-five patients were evaluable, ages 1-14 years, and 97 cycles of HDC/SCR have been completed to date. Pheresis was possible for every patient, despite their young age, with an average of 7.2 x 106 CD34+ cells/kg available to support each HDC/SCR cycle. Results. Engraftment was rapid, with median time to neutrophil engraftment of 11 days. Five patients who completed the first HDC course did not complete the second and there were four toxic deaths. With a median follow-up of 24 months from diagnosis, 38 of 55 patients (3-year EFS 59%) remain event-free. A subset of the patients received stem cells purged by CD34 selection. The engraftment and EFS of these patients are similar to the overall group. Conclusion. This work demonstrates that a tandem transplant regimen for high-risk NB is a feasible treatment strategy in children and may improve disease-free survival. (C) 2000 Wiley-Liss, Inc.

AB - Background. The majority of patients with high risk neuroblastoma (NB) still relapse. Procedure. We designed a Phase II trial for children with advanced NB utilizing a program of induction chemotherapy followed by tandem high-dose chemoradiotherapy with stem cell rescue (HDC/SCR) in rapid sequence. Fifty-five patients were evaluable, ages 1-14 years, and 97 cycles of HDC/SCR have been completed to date. Pheresis was possible for every patient, despite their young age, with an average of 7.2 x 106 CD34+ cells/kg available to support each HDC/SCR cycle. Results. Engraftment was rapid, with median time to neutrophil engraftment of 11 days. Five patients who completed the first HDC course did not complete the second and there were four toxic deaths. With a median follow-up of 24 months from diagnosis, 38 of 55 patients (3-year EFS 59%) remain event-free. A subset of the patients received stem cells purged by CD34 selection. The engraftment and EFS of these patients are similar to the overall group. Conclusion. This work demonstrates that a tandem transplant regimen for high-risk NB is a feasible treatment strategy in children and may improve disease-free survival. (C) 2000 Wiley-Liss, Inc.

KW - CD34 selection

KW - Neuroblastoma

KW - Pediatric

KW - Stem cell transplant

KW - Tandem transplant

UR - http://www.scopus.com/inward/record.url?scp=0033646847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033646847&partnerID=8YFLogxK

U2 - 10.1002/1096-911X(20001201)35:6<696::AID-MPO46>3.0.CO;2-0

DO - 10.1002/1096-911X(20001201)35:6<696::AID-MPO46>3.0.CO;2-0

M3 - Article

C2 - 11107149

AN - SCOPUS:0033646847

VL - 35

SP - 696

EP - 700

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -